WO2008015480A3 - Composition and method for modulating an immune response - Google Patents

Composition and method for modulating an immune response Download PDF

Info

Publication number
WO2008015480A3
WO2008015480A3 PCT/GB2007/050464 GB2007050464W WO2008015480A3 WO 2008015480 A3 WO2008015480 A3 WO 2008015480A3 GB 2007050464 W GB2007050464 W GB 2007050464W WO 2008015480 A3 WO2008015480 A3 WO 2008015480A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune response
polypeptide
pathogen
modulating
composition
Prior art date
Application number
PCT/GB2007/050464
Other languages
French (fr)
Other versions
WO2008015480A2 (en
Inventor
Camilo Colaco
Original Assignee
Immunobiology Ltd
Camilo Colaco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunobiology Ltd, Camilo Colaco filed Critical Immunobiology Ltd
Publication of WO2008015480A2 publication Critical patent/WO2008015480A2/en
Publication of WO2008015480A3 publication Critical patent/WO2008015480A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The present invention provides a polypeptide immunoconjugate comprising an antigenic polypeptide which is coupled to a polypeptide which is capable of binding to an Fc receptor. The antigenic polypeptide is derived from a pathogen or a pathogen product and as characterised in that it can be processed by the immune system in order to generate an immune response there against which confers protective immunity against the pathogen from which the antigenic polypeptide is derived. The invention further extends to methods for the treatment of a disease condition in a subject using the immunoconjugate of the invention.
PCT/GB2007/050464 2006-08-01 2007-08-01 Composition and method for modulating an immune response WO2008015480A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0615266.4A GB0615266D0 (en) 2006-08-01 2006-08-01 Composition and method for mediating an immune response
GB0615266.4 2006-08-01

Publications (2)

Publication Number Publication Date
WO2008015480A2 WO2008015480A2 (en) 2008-02-07
WO2008015480A3 true WO2008015480A3 (en) 2008-04-17

Family

ID=37006552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/050464 WO2008015480A2 (en) 2006-08-01 2007-08-01 Composition and method for modulating an immune response

Country Status (2)

Country Link
GB (1) GB0615266D0 (en)
WO (1) WO2008015480A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010303568B2 (en) 2009-10-09 2014-07-31 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001732A2 (en) * 1998-07-06 2000-01-13 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
WO2002042462A2 (en) * 2000-11-27 2002-05-30 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
US20030157108A1 (en) * 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
WO2004099249A2 (en) * 2003-05-02 2004-11-18 Xencor, Inc. Optimized fc variants and methods for their generation
US20050031628A1 (en) * 2003-08-08 2005-02-10 Virexx Medical Corp. Chimeric antigens for breaking host tolerance to foreign antigens
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2007107797A2 (en) * 2006-03-22 2007-09-27 Immunobiology Limited Fusion protein comprising an fc receptor binding polypeptide and an antigenic polypeptide for mediating an immune response

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001732A2 (en) * 1998-07-06 2000-01-13 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2002042462A2 (en) * 2000-11-27 2002-05-30 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
US20030157108A1 (en) * 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
WO2004099249A2 (en) * 2003-05-02 2004-11-18 Xencor, Inc. Optimized fc variants and methods for their generation
US20050031628A1 (en) * 2003-08-08 2005-02-10 Virexx Medical Corp. Chimeric antigens for breaking host tolerance to foreign antigens
WO2007107797A2 (en) * 2006-03-22 2007-09-27 Immunobiology Limited Fusion protein comprising an fc receptor binding polypeptide and an antigenic polypeptide for mediating an immune response

Also Published As

Publication number Publication date
WO2008015480A2 (en) 2008-02-07
GB0615266D0 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
WO2012045001A3 (en) Influenza virus antibodies and immunogens and uses therefor
WO2009025888A3 (en) Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
WO2011119979A3 (en) Antibodies to muc16 and methods of use thereof
WO2009039229A3 (en) Method of conferring a protective immune response to norovirus
MX348071B (en) Fc variants.
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2007100908A3 (en) Chimeric adenoviral vectors
WO2011005799A3 (en) Rna containing modified nucleotides and use thereof in vaccines
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2012007880A3 (en) Modified single domain antigen binding molecules and uses thereof
WO2008039390A3 (en) Compositions and methods for chitosan enhanced immune response
WO2010019262A3 (en) Polyvalent vaccine
WO2012003470A3 (en) Antibody formulations
WO2014140374A3 (en) Monovalent cd27 antibodies
WO2009031045A3 (en) Anti-chikungunya monoclonal antibodies and uses thereof
IL211394B (en) Chimeric fusion proteins for inducing an immune response to p.gingivalis, compositions and uses thereof
SG11201806502UA (en) Conjugate of therapeutic enzymes
WO2008033966A3 (en) Alphavirus replicon particles matched to protein antigens as immunological adjuvants
WO2006072888A3 (en) Continuous administration of epitopes derived from protein present in atherosclerotic plaque for the treatment of atherosclerosis
WO2007135441A3 (en) Apparatus and method for the assessment of neurodevelopmental disorders
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
WO2012018767A3 (en) Antibodies directed against il-17
WO2012047267A3 (en) Polyvalent immunogen
WO2008021375A3 (en) Modulators of muscarinic receptors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07766476

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07766476

Country of ref document: EP

Kind code of ref document: A2